Jasper Therapeutics, Inc. — fact timeline

Jasper Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“June 3, 2026, Jasper Therapeutics, Inc. (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the bid price for the Company’s voting common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until November 30, 2026, to regain compliance. The N”

Christian Nolet resigned as Director at Jasper Therapeutics, Inc..

“On May 15, 2026 (the “Notice Date”), Christian Nolet informed the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) that he is resigning from the Board and the committees of the Board on which he serves, effective as of the Notice Date.”

Jasper Therapeutics, Inc. reported the quarter ended March 31, 2026 results: net income net loss of $1.2 million, EPS basic and diluted net loss per share attributable to common stockholders of $0.04.

“Jasper reported a net loss of $1.2 million, or basic and diluted net loss per share attributable to common stockholders of $0.04 for the three months ended March 31, 2026.”

Jasper Therapeutics, Inc. reported the quarter and year ended December 31, 2025 results: net income a net loss of $9.1 million and $75.8 million, or basic and diluted net loss per share attributable to common stockholder, EPS $0.32 and $3.95.

“Jasper reported a net loss of $9.1 million and $75.8 million, or basic and diluted net loss per share attributable to common stockholders of $0.32 and $3.95, for the three months and year ended December 31, 2025, respectively.”

Jasper Therapeutics, Inc. announced a restructuring with charges of approximately $1.8 million - $2.2 million affecting the Company (approximately 50%).

“in chronic urticaria and is halting other clinical and preclinical programs along with the reduction in workforce. The Company estimates that it will incur approximately $1.8 million - $2.2 million of cash expenditures in connection with the corporate reorganization, which relate to severance pay, and are expected to be incurred through the quarter ending”

Svetlana Lucas was appointed as Class III Director at Jasper Therapeutics, Inc..

“Effective immediately following Dr. French’s resignation, on June 18, 2024, the Board appointed Svetlana Lucas, Ph.D. as a Class III director of the Company.”

Anna French resigned as Director at Jasper Therapeutics, Inc..

“On June 17, 2024, Anna French, D.Phil. notified the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) of her intent to resign from the Board effective as of June 18, 2024.”

Jasper Therapeutics, Inc. reported fiscal year ended December 31, 2023 results: net income $64.5 million, or basic and diluted net loss per share attributable to common stockholders of $6.18, EPS $6.18.

“Jasper reported a net loss of $16.6 million and $64.5 million, or basic and diluted net loss per share attributable to common stockholders of $1.50 and $6.18, for the three months and the year ended December 31, 2023, respectively.”

Jasper Therapeutics, Inc. entered into Underwriting Agreement with Cowen and Company, LLC and Evercore Group L.L.C. valued at Underwritten offering of 3,900,000 shares of voting common stock at $12.95 per share; gross proceeds (effective 2024-02-06).

“On February 6, 2024, Jasper Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cowen and Company, LLC and Evercore Group L.L.C., as the representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten offering (the “Offering”) of 3,900,000 shares of the Company’s voting common stock (“Common Stock”).”

Jasper Therapeutics, Inc.: Effected a 1-for-10 reverse stock split to regain compliance with Nasdaq minimum bid price requirement (effective 2024-01-04).

“The Reverse Stock Split was effective at 12:01 a.m., Eastern Time, on January 4, 2024, and the Common Stock is expected to begin trading on a Reverse Stock Split-adjusted basis on the Nasdaq Capital Market at the opening of the market on January 4, 2024.”

Jasper Therapeutics, Inc. shareholders approved Approve an amendment to the Certificate of Incorporation to effect a reverse stock split within a range of 1-for-3 to 1-for-10 at the 2023-12-15 meeting.

“On December 15, 2023, Jasper Therapeutics, Inc. (the “Company”) held a Special Meeting of Stockholders”

Thomas G. Wiggans was appointed as Chairperson of the Board at Jasper Therapeutics, Inc..

“Effective November 1, 2023, the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) appointed Thomas G. Wiggans as a Class II director of the Company. Mr. Wiggans was also appointed to serve as Chairperson of the Board.”

Jasper Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(ii)).

“October 18, 2023, Jasper Therapeutics, Inc. (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the bid price for the Company’s voting common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A)(ii), the Company has been provided an initial period of 180 calendar days, or until April 15, 2024, to regain compliance.”

Jeet Mahal changed role as Chief Operating Officer at Jasper Therapeutics, Inc..

“the Board approved the transition of Jeet Mahal, the Company’s Chief Financial Officer and Chief Operating Officer, to serve solely as the Company’s Chief Operating Officer.”

Herb Cross was appointed as Chief Financial Officer and Corporate Secretary at Jasper Therapeutics, Inc..

“On September 21, 2023, the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) appointed Herb Cross, age 51 , as its Chief Financial Officer and Corporate Secretary.”

Jasper Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income Net Loss: For the quarter ended June 30, 2023, net loss was $16.1 million compared to net loss of $10.4 million for the.

“On August 11, 2023, Jasper Therapeutics, Inc. issued a press release reporting its financial results for the quarter ended June 30, 2023 and providing a business update.”

Scott Brun was appointed as Class I Director at Jasper Therapeutics, Inc..

“Effective June 20, 2023, the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) appointed Scott Brun, M.D., as a Class I director of the Company.”

Jasper Therapeutics, Inc.: Amended certificate of incorporation to add officer exculpation provisions under new Delaware law (effective 2023-06-08).

“On June 7, 2023, the Company held its 2023 Annual Meeting of Stockholders (the “Meeting”). At the Meeting, the Company’s stockholders approved an amendment to the Company’s Second Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) to reflect new Delaware law provisions regarding officer exculpation (the “Amendment”).”

Jasper Therapeutics, Inc. shareholders approved To approve an amendment to the Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation. at the 2023-06-07 meeting.

“Proposal No. 3 : To approve an amendment to the Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation. Votes For Votes Against Abstentions Broker Non-Votes 73,923,961 7,116,389 23,804 10,839,662”

Jasper Therapeutics, Inc. shareholders approved To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2023. at the 2023-06-07 meeting.

“Proposal No. 2: To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2023. Votes For Votes Against Abstentions 91,856,308 37,101 10,407”

Jasper Therapeutics, Inc. shareholders approved To elect two Class II directors to serve until the 2026 annual meeting of stockholders and until their successors are duly elected and qualified. at the 2023-06-07 meeting.

“Director Nominee Votes For Votes Withheld Broker Non-Votes Anna French, D. Phil. 69,570,975 11,493,179 10,839,662 Judith Shizuru, M.D., Ph.D. 72,204,829 8,859,325 10,839,662”

Jasper Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income Net loss was $14.3 million.

“On May 12, 2023, Jasper Therapeutics, Inc. issued a press release reporting its financial results for the quarter ended March 31, 2023 and providing a business update.”

Jasper Therapeutics, Inc. reported the fiscal year ended December 31, 2022 results: net income Net loss was $37.7 million.

“Jasper Therapeutics, Inc. issued a press release reporting its financial results for the fiscal year ended December 31, 2022”

Jasper Therapeutics, Inc.: Adopted third amended and restated bylaws to address universal proxy rules and enhance disclosure requirements for director nominations and business proposals by stockholders (effective 2023-02-16).

“On and effective February 16, 2023, the Board approved and adopted an amendment and restatement of the Company’s second amended and restated bylaws (as so amended and restated, the “Third Amended and Restated Bylaws”), effective as of February 16, 2023.”

Vishal Kapoor was appointed as Class I Director at Jasper Therapeutics, Inc..

“Effective February 16, 2023, the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) appointed Vishal Kapoor as a Class I director of the Company.”

Jasper Therapeutics, Inc. entered into Underwriting Agreement with Credit Suisse Securities (USA) LLC, William Blair & Company, L.L.C. and Oppenheimer & Co. Inc. valued at approximately $90 million (effective 2023-01-25).

“On January 25, 2023, Jasper Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Credit Suisse Securities (USA) LLC, William Blair & Company, L.L.C. and Oppenheimer & Co. Inc., as the representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 60,000,000 shares of the Company’s voting common stock, $0.0001 par value per share (“Common Stock”).”

Jasper Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income $11.9 million.

“Jasper Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update”

Jasper Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“November 3, 2022, Jasper Therapeutics, Inc. (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the bid price for the Company’s voting common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until May 2, 2023, to regain compliance. The Not”

Kevin N. Heller was terminated as Executive Vice President, Research and Development at Jasper Therapeutics, Inc..

“Dr. Heller’s employment with the Company will terminate, effective May 17, 2022.”

Jeet Mahal changed role as Chief Operating Officer and Chief Financial Officer at Jasper Therapeutics, Inc..

“On March 18, 2022, the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) approved the promotion of Jeet Mahal, age 50, the Company’s Chief Financial Officer and Chief Business Officer, to Chief Operating Officer and Chief Financial Officer, effective March 21, 2022.”

William Lis was appointed as Chairperson of the Board at Jasper Therapeutics, Inc..

“Mr. Lis will continue serving as a Class III director of the Company and will commence serving as a non-employee Chairperson of the Company’s Board of Directors (the “Board”).”

Ronald Martell was appointed as President and Chief Executive Officer at Jasper Therapeutics, Inc..

“On March 7, 2022, in connection with the appointment of Ronald Martell as the President and Chief Executive Officer of Jasper Therapeutics, Inc. (the “Company”),”

William Lis was terminated as Chief Executive Officer at Jasper Therapeutics, Inc..

“Mr. Lis’ employment with the Company will terminate as of March 15, 2022, at which time, Mr. Lis will continue serving as a Class III director of the Company and will commence serving as a non-employee Chairperson of the Company’s Board of Directors (the “Board”).”

William Lis changed role as non-executive Chairperson at Jasper Therapeutics, Inc..

“William Lis, who is serving as President, Chief Executive Officer and Executive Chairman of the Board, will become the non-executive Chairperson of the Board.”

Ronald Martell was appointed as Class III director at Jasper Therapeutics, Inc..

“appointed Ronald Martell, age 60, as the Company’s President and Chief Executive Officer and as a Class III director of the Company, in each case effective upon commencement of his employment with the Company, which is expected to be March 15, 2022.”

Ronald Martell was appointed as President and Chief Executive Officer at Jasper Therapeutics, Inc..

“appointed Ronald Martell, age 60, as the Company’s President and Chief Executive Officer and as a Class III director of the Company, in each case effective upon commencement of his employment with the Company, which is expected to be March 15, 2022.”

Kevin N. Heller, M.D. was appointed as Executive Vice President, Research and Development at Jasper Therapeutics, Inc..

“Kevin N. Heller, M.D. Executive Vice President, Research and Development”

Jeet Mahal was appointed as Chief Financial and Business Officer and Corporate Secretary at Jasper Therapeutics, Inc..

“Jeet Mahal Chief Financial and Business Officer and Corporate Secretary”

William Lis was appointed as President, Chief Executive Officer and Executive Chairman at Jasper Therapeutics, Inc..

“William Lis President, Chief Executive Officer and Executive Chairman of the New Jasper Board”

Vishal Kapoor departed as Executive Officer at Jasper Therapeutics, Inc..

“each of Bala Venkataraman, Kenneth Clifford and Vishal Kapoor ceased serving as an executive officer of AMHC.”

Kenneth Clifford departed as Executive Officer at Jasper Therapeutics, Inc..

“each of Bala Venkataraman, Kenneth Clifford and Vishal Kapoor ceased serving as an executive officer of AMHC.”

Bala Venkataraman departed as Executive Officer at Jasper Therapeutics, Inc..

“each of Bala Venkataraman, Kenneth Clifford and Vishal Kapoor ceased serving as an executive officer of AMHC.”